|Day Low/High||7.41 / 7.85|
|52 Wk Low/High||5.84 / 14.95|
Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Dr. Phillip Chan Discusses the Potential of CytoSorb(R) to Revolutionize Critical Care Medicine, the Strategy in Europe, and Plans for a US Pivotal Study
Q1 2013 CytoSorb(R) Product Revenue to Exceed Entire 2012 CytoSorb(R) Product Revenue
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.